• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Trials demonstrate effective antibody-based treatment for psoriasis: AMAGINE-2 and 3 Study

byTomi JunandShaidah Deghan, MSc. MD
October 2, 2015
in Chronic Disease, Dermatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Brodalumab was more effective than either placebo or ustekinumab at reducing the severity of psoriasis after 12 weeks of treatment.

2. Consistent dosing of brodalumab helps to extend the treatment response to 1 year.

3. Treatment with brodalumab was associated with alterations in the immune system and greater frequency of certain infections, though in general the risk of infection was not different from that of ustekinumab.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Psoriasis is an inflammatory skin disease characterized by red, scaly and itchy plaques. Studies have shown that interleukin-17, a molecule involved in immune system signaling, plays a role in promoting psoriasis. Brodalumab is an antibody which targets a component of the interleukin-17 receptor and inhibits interleukin-17 signaling. Preliminary studies have shown that brodalumab can reverse psoriasis through its anti-interleukin-17 effect.

The AMAGINE-2 and 3 trials were two identically designed trials conducted at nearly 300 different centers around the world. The trials compared brodalumab against ustekinumab, another antibody-based treatment for psoriasis, and placebo. Both trials produced broadly similar results and showed that brodalumab at a dose of 210mg every 2 weeks was superior to both ustekinumab and placebo in reducing the severity of psoriasis symptoms at 12 weeks. The trials also showed that brodalumab therapy had to be sustained in order to maintain the treatment response.

The safety profile of brodalumab did not differ significantly from that of ustekinumab. The rates of serious infection were approximately 1 per 100 pts/yr of treatment with either brodalumab or ustekinumab.

RELATED REPORTS

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

Click to read the study, published today in NEJM

Relevant Reading: Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody

In-Depth [randomized controlled trial]: The AMAGINE-2 and 3 trials were identically-designed randomized, double-blind, placebo-controlled phase 3 trials. Each trial enrolled nearly 1900 participants aged 18-75 with moderate-to-severe plaque psoriasis for at least 6 months and with involvement of at least 10% of the body-surface area. Severity of psoriasis was evaluated with the psoriasis area and severity index (PASI) and the static physician’s global assessment (sPGA) score. Patients were randomized to receive placebo, ustekinumab, lower-dose brodalumab (140 mg every 2 weeks) or higher-dose brodalumab (210mg every 2 weeks) for 12 weeks.

Brodalumab at either the higher or lower dose was significantly superior compared to the placebo for attainment of a 75% or greater reduction in PASI score (AMAGINE-2: 86% and 67% vs. 8%, p<0.001; AMAGINE-3: 85% and 69% vs. 6%, p<0.001). Brodalumab at either dose was superior to placebo for attainment of an sPGA score of 0 or 1 (clear or almost clear skin). Brodalumab at either dose was also superior to ustekinumab for attainment of a 100% reduction in baseline PASI score (AMAGINE-2 44% and 26% vs. 22%, p<0.001; AMAGINE-3: 37% and 27% vs. 19%, p<0.001). 

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Brodalumabpsoriasis
Previous Post

Cardiac risk factors more prevalent in obese children

Next Post

Small molecule drug targets Clostridium difficile toxins [PreClinical]

RelatedReports

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention
StudyGraphics

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

January 28, 2022
#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease
StudyGraphics

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

December 16, 2021
#VisualAbstract Risk of serious infection in patients with moderate to severe psoriasis is associated with the type of biologic treatment
StudyGraphics

#VisualAbstract Risk of serious infection in patients with moderate to severe psoriasis is associated with the type of biologic treatment

August 13, 2021
Next Post
Molecular testing for Clostridium difficile may not predict disease activity

Small molecule drug targets Clostridium difficile toxins [PreClinical]

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ

Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants

Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.